- In July 2023, Marinus Pharmaceuticals received orphan drug designation from the U.S. FDA for ganaxolone, a treatment aimed at managing Lennox-Gastaut syndrome. This designation highlights the drug’s potential to address an unmet need in treating this rare and severe form of epilepsy. The approval is expected to expedite its development and enhance its market prospects for Lennox-Gastaut syndrome treatment
